标题
Cetuximab for treating non-small cell lung cancer
作者
关键词
-
出版物
EXPERT OPINION ON BIOLOGICAL THERAPY
Volume 18, Issue 4, Pages 483-493
出版商
Informa UK Limited
发表日期
2018-03-14
DOI
10.1080/14712598.2018.1452906
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- MA09.11 Efficacy and Safety of Necitumumab and Pembrolizumab Combination Therapy in Stage IV Nonsquamous Non-Small Cell Lung Cancer (NSCLC)
- (2017) Benjamin Besse et al. Journal of Thoracic Oncology
- Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer
- (2017) Scott J. Antonia et al. NEW ENGLAND JOURNAL OF MEDICINE
- Precision Diagnosis and Treatment for Advanced Non–Small-Cell Lung Cancer
- (2017) Martin Reck et al. NEW ENGLAND JOURNAL OF MEDICINE
- Same Data; Different Interpretations
- (2016) Bishal Gyawali et al. JOURNAL OF CLINICAL ONCOLOGY
- Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial
- (2016) Louis Fehrenbacher et al. LANCET
- Overcoming EGFR(T790M) and EGFR(C797S) resistance with mutant-selective allosteric inhibitors
- (2016) Yong Jia et al. NATURE
- The EGFR-specific antibody cetuximab combined with chemotherapy triggers immunogenic cell death
- (2016) Chiara Pozzi et al. NATURE MEDICINE
- Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer
- (2016) Martin Reck et al. NEW ENGLAND JOURNAL OF MEDICINE
- Prospective Evaluation of Cetuximab-Mediated Antibody-Dependent Cell Cytotoxicity in Metastatic Colorectal Cancer Patients Predicts Treatment Efficacy
- (2016) A. M. Trotta et al. Cancer Immunology Research
- PD-L1 expression in non-small cell lung cancer: Correlations with genetic alterations
- (2016) Andreas H. Scheel et al. OncoImmunology
- 96O * DETERMINING THE PREVALENCE OF EGFR MUTATIONS IN ASIAN AND RUSSIAN PATIENTS (PTS) WITH ADVANCED NON-SMALL-CELL LUNG CANCER (ANSCLC) OF ADENOCARCINOMA (ADC) AND NON-ADC HISTOLOGY: IGNITE STUDY
- (2015) B. Han et al. ANNALS OF ONCOLOGY
- Cilengitide combined with cetuximab and platinum-based chemotherapy as first-line treatment in advanced non-small-cell lung cancer (NSCLC) patients: results of an open-label, randomized, controlled phase II study (CERTO)
- (2015) J. Vansteenkiste et al. ANNALS OF ONCOLOGY
- The relevance of ADCC for EGFR targeting: A review of the literature and a clinically-applicable method of assessment in patients
- (2015) Martino Monteverde et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Concurrent Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer: What Is the Best Regimen?
- (2015) Wilfried Ernst Erich Eberhardt JOURNAL OF CLINICAL ONCOLOGY
- Final Overall Survival Results from a Phase III, Randomized, Placebo-Controlled, Parallel-Group Study of Gefitinib Versus Placebo as Maintenance Therapy in Patients with Locally Advanced or Metastatic Non–Small-Cell Lung Cancer (INFORM; C-TONG 0804)
- (2015) Hongyun Zhao et al. Journal of Thoracic Oncology
- Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study
- (2015) Jeffrey D Bradley et al. LANCET ONCOLOGY
- Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials
- (2015) James Chih-Hsin Yang et al. LANCET ONCOLOGY
- Molecular properties of human IgG subclasses and their implications for designing therapeutic monoclonal antibodies against infectious diseases
- (2015) Vashti Irani et al. MOLECULAR IMMUNOLOGY
- Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
- (2015) Hossein Borghaei et al. NEW ENGLAND JOURNAL OF MEDICINE
- Necitumumab in Metastatic Squamous Cell Lung Cancer
- (2015) Daniel A. Goldstein et al. JAMA Oncology
- Clinical massively parallel next-generation sequencing analysis of 409 cancer-related genes for mutations and copy number variations in solid tumours
- (2014) R R Singh et al. BRITISH JOURNAL OF CANCER
- A Phase I Study of Concurrent Individualized, Isotoxic Accelerated Radiotherapy and Cisplatin–Vinorelbine–Cetuximab in Patients With Stage III Non–Small-Cell Lung Cancer
- (2014) Anne-Marie C. Dingemans et al. Journal of Thoracic Oncology
- Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial
- (2014) Edward B Garon et al. LANCET
- Ceritinib in ALK-Rearranged Non–Small-Cell Lung Cancer
- (2014) Alice T. Shaw et al. NEW ENGLAND JOURNAL OF MEDICINE
- First-Line Crizotinib versus Chemotherapy in ALK-Positive Lung Cancer
- (2014) Benjamin J. Solomon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Crizotinib in ROS1-Rearranged Non–Small-Cell Lung Cancer
- (2014) Alice T. Shaw et al. NEW ENGLAND JOURNAL OF MEDICINE
- Weekly and every 2 weeks cetuximab maintenance therapy after platinum-based chemotherapy plus cetuximab as first-line treatment for non-small cell lung cancer: randomized non-comparative phase IIIb NEXT trial
- (2014) David F. Heigener et al. Targeted Oncology
- Dual Inhibition of EGFR with Afatinib and Cetuximab in Kinase Inhibitor-Resistant EGFR-Mutant Lung Cancer with and without T790M Mutations
- (2014) Y. Y. Janjigian et al. Cancer Discovery
- Phase II Trial of Carboplatin, Paclitaxel, Cetuximab, and Bevacizumab Followed by Cetuximab and Bevacizumab in Advanced Nonsquamous Non–Small-Cell Lung Cancer: SWOG S0536
- (2013) Edward S. Kim et al. Journal of Thoracic Oncology
- Docetaxel or pemetrexed with or without cetuximab in recurrent or progressive non-small-cell lung cancer after platinum-based therapy: a phase 3, open-label, randomised trial
- (2013) Edward S Kim et al. LANCET ONCOLOGY
- Phase II study of pemetrexed and cisplatin plus cetuximab followed by pemetrexed and cetuximab maintenance therapy in patients with advanced nonsquamous non-small cell lung cancer
- (2013) Gerald Schmid-Bindert et al. LUNG CANCER
- Meta-analysis of individual patient data from randomized trials of chemotherapy plus cetuximab as first-line treatment for advanced non-small cell lung cancer
- (2013) Jean-Louis Pujol et al. LUNG CANCER
- Additional weekly Cetuximab to concurrent chemoradiotherapy in locally advanced non-small cell lung carcinoma: Efficacy and safety outcomes of a randomized, multi-center phase II study investigating
- (2013) Michel M. van den Heuvel et al. RADIOTHERAPY AND ONCOLOGY
- Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal
- (2013) J. Gao et al. Science Signaling
- Design of a Phase III Clinical Trial with Prospective Biomarker Validation: SWOG S0819
- (2012) M. W. Redman et al. CLINICAL CANCER RESEARCH
- A review of clinical trials of cetuximab combined with radiotherapy for non-small cell lung cancer
- (2012) Carsten Nieder et al. Radiation Oncology
- Combined treatment of nonsmall cell lung cancer NSCLC stage III with intensity-modulated RT radiotherapy and cetuximab
- (2011) Alexandra D. Jensen et al. CANCER
- EGF Receptor Inhibition Radiosensitizes NSCLC Cells by Inducing Senescence in Cells Sustaining DNA Double-Strand Breaks
- (2011) M. Wang et al. CANCER RESEARCH
- 9001 ORAL A Retrospective Subgroup Analysis of EGFR Immunohistochemistry (IHC) Expression by Histo-Score Correlated to Outcomes From the BMS099 1st Line Phase III NSCLC Trial of Cetuximab (Cet) Plus Carboplatin/Taxane
- (2011) T. Lynch et al. EUROPEAN JOURNAL OF CANCER
- Randomized Phase II Study of Pemetrexed, Carboplatin, and Thoracic Radiation With or Without Cetuximab in Patients With Locally Advanced Unresectable Non–Small-Cell Lung Cancer: Cancer and Leukemia Group B Trial 30407
- (2011) Ramaswamy Govindan et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Study of Cetuximab in Combination With Chemoradiation in Patients With Stage IIIA/B Non–Small-Cell Lung Cancer: RTOG 0324
- (2011) George R. Blumenschein et al. JOURNAL OF CLINICAL ONCOLOGY
- Molecular biomarkers in non-small-cell lung cancer: a retrospective analysis of data from the phase 3 FLEX study
- (2011) Kenneth J O'Byrne et al. LANCET ONCOLOGY
- Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
- (2011) Caicun Zhou et al. LANCET ONCOLOGY
- EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study
- (2011) Robert Pirker et al. LANCET ONCOLOGY
- Cetuximab-based Therapy is Effective in Chemotherapy-naïve Patients with Advanced and Metastatic Non-small-cell Lung Cancer: A Meta-analysis of Randomized Controlled Trials
- (2011) Ezzeldin M. Ibrahim et al. LUNG
- A phase II study of cetuximab and radiation in elderly and/or poor performance status patients with locally advanced non-small-cell lung cancer (N0422)
- (2010) A. Jatoi et al. ANNALS OF ONCOLOGY
- Inter-observer agreement between dermatologists and oncologists in assessing dermatological toxicities in patients with metastatic colorectal cancer treated by cetuximab-based chemotherapies: A pilot comparative study
- (2010) Jacqueline Duffour et al. EUROPEAN JOURNAL OF CANCER
- Cetuximab and First-Line Taxane/Carboplatin Chemotherapy in Advanced Non–Small-Cell Lung Cancer: Results of the Randomized Multicenter Phase III Trial BMS099
- (2010) Thomas J. Lynch et al. JOURNAL OF CLINICAL ONCOLOGY
- Personalized Medicine in Non–Small-Cell Lung Cancer: IsKRASa Useful Marker in Selecting Patients for Epidermal Growth Factor Receptor–Targeted Therapy?
- (2010) Patrick J. Roberts et al. JOURNAL OF CLINICAL ONCOLOGY
- Analysis of Potential Predictive Markers of Cetuximab Benefit in BMS099, a Phase III Study of Cetuximab and First-Line Taxane/Carboplatin in Advanced Non–Small-Cell Lung Cancer
- (2010) Shirin Khambata-Ford et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Selection Design Trial of Concurrent Chemotherapy and Cetuximab Versus Chemotherapy Followed by Cetuximab in Advanced-Stage Non–Small-Cell Lung Cancer: Southwest Oncology Group Study S0342
- (2010) Roy S. Herbst et al. JOURNAL OF CLINICAL ONCOLOGY
- Cetuximab Monotherapy in Patients with Advanced Non-small Cell Lung Cancer After Prior Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy
- (2010) Joel W. Neal et al. Journal of Thoracic Oncology
- Pemetrexed with or without Matuzumab as Second-Line Treatment for Patients with Stage IIIB/IV Non-small Cell Lung Cancer
- (2010) Joan H. Schiller et al. Journal of Thoracic Oncology
- Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study
- (2010) Federico Cappuzzo et al. LANCET ONCOLOGY
- Concurrent cetuximab and radiotherapy after docetaxel–cisplatin induction chemotherapy in stage III NSCLC: Satellite—A phase II study from the Swedish Lung Cancer Study Group
- (2010) A. Hallqvist et al. LUNG CANCER
- EGFR fluorescence in situ hybridisation assay: guidelines for application to non-small-cell lung cancer
- (2009) M Varella-Garcia et al. JOURNAL OF CLINICAL PATHOLOGY
- How Much Is Life Worth: Cetuximab, Non-Small Cell Lung Cancer, and the $440 Billion Question
- (2009) T. Fojo et al. JNCI-Journal of the National Cancer Institute
- Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial
- (2009) Robert Pirker et al. LANCET
- Dual Inhibition of the Epidermal Growth Factor Receptor Pathway with Cetuximab and Erlotinib: A Phase I Study in Patients with Advanced Solid Malignancies
- (2009) M. J. Guarino et al. ONCOLOGIST
- Specificity and affinity of human Fc receptors and their polymorphic variants for human IgG subclasses
- (2008) P. Bruhns et al. BLOOD
- IncreasedEGFRGene Copy Number Detected by Fluorescent In Situ Hybridization Predicts Outcome in Non–Small-Cell Lung Cancer Patients Treated With Cetuximab and Chemotherapy
- (2008) Fred R. Hirsch et al. JOURNAL OF CLINICAL ONCOLOGY
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started